Doximity's stock price has fallen from $65 to $25 in six months, a decline attributed mainly to market overreaction and short-term uncertainties rather than weakening business fundamentals. The company maintains strong financial health with 90% gross margins, about 30% net margins, and solid cash generation, supported by a dominant network of U.S. healthcare professionals. Although recent growth has slowed and there are concerns about pharmaceutical client budgets, Doximity remains asset-light with minimal downside risk and good liquidity. The stock is rated a cautious buy due to undervaluation and resilient profitability, while investors should watch developments in AI monetization and client budget trends.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
Latham Group is rated a Buy as it implements a new CEO-led strategy focusing on expanding its core market, increasing presence in the southern U.S., adopting automatic pool covers, and pursuing mergers and acquisitions. Despite challenges in the depr...
NYDIG projects Bitcoin might fall to $38,000-$39,000 by October 2026 if the current 2025-26 market decline matches the depth of the 2022 bear market. Bitcoin is currently trading near $64,500, down about 30% this year and roughly 50% below its Octobe...
PepsiCo is rated a strong buy due to its attractive combination of dividend yield, earnings growth, and undervaluation. The company is projected to achieve a forward compound annual growth rate (CAGR) between 13.7% and 18.2%, supported by dividend in...
